Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GREEN
2024-514352-32-00Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Glenzocimab + mechanical thrombectomy with Placebo + mechanical thrombectomy (2 arms). Primary endpoint: Primary functional outcome (mRS shift at day 90). Started Oct 2024; status: completed.
02
Drugs
glenzocimab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2024-514352-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514352-32-00.